Considering gene signature assays can become routine in the clinical management of ER+ breast cancer patients, such as MammaPrint and OncotypeDx, specific gene signatures that are predictive of therapy with CDK4/6 inhibitors may be defined and developed[27,29]. The gene discussed is ESR1; the disease is breast carcinoma.